Search

Your search keyword '"Munk, H. L."' showing total 20 results
Start Over Author "Munk, H. L."
20 results on '"Munk, H. L."'

1. POS1226 CLINICAL FACTORS ASSOCIATED WITH A POSITIVE SARS-CoV-19 TEST AND WITH FREQUENT TESTING DURING THE COVID-19 PANDEMIC IN >10.000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. RESULTS FROM A NATIONWIDE SURVEY FROM THE DANISH DANBIO REGISTRY

Author

Glintborg, B., primary, Jensen, D. V., additional, Terslev, L., additional, Hendricks, O., additional, Østergaard, M., additional, Rasmussen, S. H., additional, Pfeiffer-Jensen, M., additional, Adelsten, T., additional, Colic, A., additional, Danebod, K., additional, Kildemand, M., additional, Loft, A. G., additional, Munk, H. L., additional, Pedersen, J. K., additional, Østgård, R., additional, Sørensen, C. M., additional, Steen Krogh, N., additional, Nørgaard Agerbo, J., additional, Ziegler, C., additional, and Hetland, M. L., additional

Published
2022
Full Text
View/download PDF

2. OP0065 INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY

Author

Nabi, H., primary, Hetland, M. L., additional, Loft, A. G., additional, Hendricks, O., additional, Jensen, D., additional, Pedersen, J. K., additional, Just, S. A., additional, Danebod, K., additional, Munk, H. L., additional, Kristensen, S., additional, Manilo, N., additional, Colic, A., additional, Linauskas, A., additional, Thygesen, P. H., additional, Christensen, L. B., additional, Høgberget Kalisz, M., additional, Lomborg, N., additional, Grydehøj, J., additional, Raun, J., additional, Ahmed, R., additional, Mehnert, F., additional, Steen Krogh, N., additional, and Glintborg, B., additional

Published
2022
Full Text
View/download PDF

3. POS0373 WHO ARE IN AND WHO ARE NOT? CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES ACCEPTING AN ONLINE SYSTEM FOR REMOTELY ENTERING PATIENT REPORTED OUTCOMES. EXPERIENCE FROM THE DANISH DANBIO REGISTRY

Author

Glintborg, B., primary, Jensen, D. V., additional, Terslev, L., additional, Hendricks, O., additional, Østergaard, M., additional, Rasmussen, S. H., additional, Pfeiffer-Jensen, M., additional, Adelsten, T., additional, Colic, A., additional, Danebod, K., additional, Kildemand, M., additional, Loft, A. G., additional, Munk, H. L., additional, Pedersen, J. K., additional, Østgård, R., additional, Sørensen, C. M., additional, Steen Krogh, N., additional, Nørgaard Agerbo, J., additional, Ziegler, C., additional, and Hetland, M. L., additional

Published
2022
Full Text
View/download PDF

4. POS0644 IMPACT OF FIBRE AND RED/PROCESSED MEAT INTAKE ON TREATMENT OUTCOMES AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASES INITIATING BIOLOGICAL THERAPY: A PROSPECTIVE COHORT STUDY

Author

Overgaard, S. H., primary, Sorensen, S., additional, Munk, H. L., additional, Nexøe, A. B., additional, Glerup, H., additional, Henriksen, R. H., additional, Guldmann, T., additional, Pedersen, N., additional, Saboori, S., additional, Hvid, L., additional, Dahlerup, J. F., additional, Hvas, C. L., additional, Jawhara, M., additional, Andersen, K. W., additional, Kristian Pedersen, A., additional, Nielsen, O. H., additional, Bergenheim, F. H., additional, Brodersen, J. B., additional, Heitmann, B. L., additional, Halldorsson, T. I., additional, Holmskov, U., additional, Bygum, A., additional, Christensen, R., additional, Kjeldsen, J., additional, Ellingsen, T., additional, and Andersen, V., additional

Published
2022
Full Text
View/download PDF

5. POS1197 REMOTE AND PHYSICAL CONSULTATIONS DURING THE FIRST 15 MONTHS OF THE COVID-19 PANDEMIC: USE AND PATIENT-SATISFACTION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES FOLLOWED IN THE DANBIO REGISTRY

Author

Glintborg, B., primary, Jensen, D. V., additional, Terslev, L., additional, Hendricks, O., additional, Østergaard, M., additional, Rasmussen, S. H., additional, Pfeiffer-Jensen, M., additional, Adelsten, T., additional, Colic, A., additional, Danebod, K., additional, Kildemand, M., additional, Loft, A. G., additional, Munk, H. L., additional, Pedersen, J. K., additional, Østgård, R., additional, Sørensen, C. M., additional, Steen Krogh, N., additional, Nørgaard Agerbo, J., additional, Ziegler, C., additional, and Hetland, M. L., additional

Published
2022
Full Text
View/download PDF

7. Multiple infliximab biosimilar switches:results following a nationwide switch from originator infliximab to biosimilar CT-P13, and subsequently to biosimilar GP1111, in real-world patients with inflammatory arthritis followed in the Danish DANBIO registry

Author

Nabi, H., Glintborg, B., Loft, A. G., Hendricks, O., Pedersen, J. K., Just, S. A., Ahmed, R., Danebod, K., Munk, H. L., Colic, A., Linauskas, A., Jensen, D. V., Christensen, L. B., Manilo, N., Lomborg, N., Kristensen, S., Mehnert, F., Krogh, N. S., and Hetland, M. L.

Published
2021
Full Text
View/download PDF

8. Anxiety and concerns related to the work situation during the covid-19 pandemic in > 5,000 patients with inflammatory rheumatic disease followed in the danish danbio registry, results from a nationwide questionnaire

Author

Glintborg, B., Jensen, D. V., Engel, S., Terslev, L., Jensen, M. Pfeiffer, Hendricks, O., Ostergaard, M., Rasmussen, S. H., Adelsten, T., Colic, A., Danebod, K., Kildemand, M., Loft, A. G., Munk, H. L., Pedersen, J. K., Ostgard, R., Sorensen, C. M., Krogh, N. Steen, Agerbo, J. Norgaard, Ziegler, C., and Hetland, M. L.

Published
2021
Full Text
View/download PDF

9. Self-protection strategies, health behavior and disease activity during the first wave, re-opening and second wave of the covid-19 pandemic in > 7000 Danish patients with inflammatory arthritis

Author

Glintborg, B., Jensen, D. V., Engel, S., Terslev, L., Jensen, M. Pfeiffer, Hendricks, O., Ostergaard, M., Rasmussen, S. H., Adelsten, T., Danebod, K., Colic, A., Kildemand, M., Loft, A. G., Munk, H. L., Pedersen, K., Ostgard, R., Sorensen, C. M., Krogh, N. Steen, Agerbo, J. Norgaard, Ziegler, C., and Hetland, M. L.

Published
2021
Full Text
View/download PDF

10. Efficacy and safety of faecal microbiota tranplantation for active peripheral psoriatic arthritis:A randomised sham-controlled trial

Author

Kragsnaes, M. Skov, Kjeldsen, J., Horn, H. C., Munk, H. L., Pedersen, J. K., Just, S. A., Ahlquist, P., Pedersen, F. Moeller, De Wit, M., Moller, S., Andersen, V., Kristiansen, K., Holt, H. M., Holm, D. Kinggaard, Christensen, R., and Ellingsen, T.

Abstract

Background: Although causality remains to be established, targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel therapeutic option for treatment of extra-intestinal inflammatory diseases.1Objectives: In this proof-of-concept study, we evaluated efficacy and safety of FMT in psoriatic arthritis (PsA).2Methods: In this double-blind, parallel-group, sham-controlled, superiority trial, we randomly allocated (1:1) adults with active peripheral PsA (≥3 swollen joints) despite ongoing treatment with methotrexate to one gastroscopic-guided FMT or sham transplantation into the duodenum. The transplants (50 g faeces) came from one of four healthy, thoroughly screened, anonymous stool donors.3 The primary efficacy endpoint was the proportion of participants experiencing treatment failure (i.e., needing treatment intensification) through 26 weeks. The first key secondary endpoint was change in Health Assessment Questionnaire Disability Index (HAQ-DI) score from baseline to week 26. Safety was monitored throughout the trial. Trial registration number: NCT03058900, ClinicalTrials.gov.Results: Of 97 screened, 31 (32%) underwent randomisation (15 allocated to FMT), all received the assigned intervention, and 30 (97%) completed the 26-week clinical evaluation (Table 1). Treatment failure occurred more frequently in the FMT group than in the sham group (9 [60%] vs 3 [19%]; risk ratio, 3.20; 95% CI, 1.06 to 9.62; P=0.018). During the entire 26 weeks of observation, the rate of the treatment failures was significantly higher in the FMT than in the sham group, see figure 1. Improvement in HAQ-DI score differed between groups (0.07 vs 0.30) by 0.23 points (95% CI, 0.02 to 0.44; P=0.031) in favour of sham. No serious adverse events were observed.Conclusion: In this first interventional randomised controlled trial of FMT in immune-mediated arthritis, FMT was inferior to sham in treating active peripheral PsA. FMT did not appear to result in serious adverse events.

Published
2021
Full Text
View/download PDF

11. OP0010 EFFICACY AND SAFETY OF FAECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS: A RANDOMISED SHAM-CONTROLLED TRIAL

Author

Skov Kragsnaes, M., primary, Kjeldsen, J., additional, Horn, H. C., additional, Munk, H. L., additional, Pedersen, J. K., additional, Just, S. A., additional, Ahlquist, P., additional, Moeller Pedersen, F., additional, De Wit, M., additional, Möller, S., additional, Andersen, V., additional, Kristiansen, K., additional, Holt, H. M., additional, Kinggaard Holm, D., additional, Christensen, R., additional, and Ellingsen, T., additional

Published
2021
Full Text
View/download PDF

12. POS0056 ANXIETY AND CONCERNS RELATED TO THE WORK SITUATION DURING THE COVID-19 PANDEMIC IN >5,000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE FOLLOWED IN THE DANISH DANBIO REGISTRY, RESULTS FROM A NATIONWIDE QUESTIONNAIRE

Author

Glintborg, B., primary, Jensen, D. V., additional, Engel, S., additional, Terslev, L., additional, Pfeiffer Jensen, M., additional, Hendricks, O., additional, Østergaard, M., additional, Rasmussen, S. H., additional, Adelsten, T., additional, Colic, A., additional, Danebod, K., additional, Kildemand, M., additional, Loft, A. G., additional, Munk, H. L., additional, Pedersen, J. K., additional, Østgård, R., additional, Sørensen, C. M., additional, Steen Krogh, N., additional, Nørgaard Agerbo, J., additional, Ziegler, C., additional, and Hetland, M. L., additional

Published
2021
Full Text
View/download PDF

13. AB0924-PARE EXPERIENCES AND PERCEPTIONS OF PATIENTS WITH PSORIATIC ARTHRITIS PARTICIPATING IN A TRIAL OF FAECAL MICROBIOTA TRANSPLANTATION: A NESTED QUALITATIVE STUDY

Author

Skov Kragsnaes, M., primary, Theodor Sødergren, S., additional, Kjeldsen, J., additional, Horn, H. C., additional, Munk, H. L., additional, Pedersen, J. K., additional, Schufri Klinkby, C., additional, De Wit, M., additional, Gram Ahlmark, N., additional, Tjørnhøj-Thomsen, T., additional, and Ellingsen, T., additional

Published
2021
Full Text
View/download PDF

14. POS1170 SELF-PROTECTION STRATEGIES, HEALTH BEHAVIOR AND DISEASE ACTIVITY DURING THE FIRST WAVE, RE-OPENING AND SECOND WAVE OF THE COVID-19 PANDEMIC IN >7000 DANISH PATIENTS WITH INFLAMMATORY ARTHRITIS

Author

Glintborg, B., primary, Jensen, D. V., additional, Engel, S., additional, Terslev, L., additional, Pfeiffer Jensen, M., additional, Hendricks, O., additional, Østergaard, M., additional, Rasmussen, S. H., additional, Adelsten, T., additional, Danebod, K., additional, Colic, A., additional, Kildemand, M., additional, Loft, A. G., additional, Munk, H. L., additional, Pedersen, J. K., additional, Østgård, R., additional, Sørensen, C. M., additional, Steen Krogh, N., additional, Nørgaard Agerbo, J., additional, Ziegler, C., additional, and Hetland, M. L., additional

Published
2021
Full Text
View/download PDF

15. No diagnostic utility of antibody patterns against Klebsiella pneumoniae capsular serotypes in patients with axial spondyloarthritis vs. patients with non-specific low back pain:a cross-sectional study

Author

Hermansen, L T, Loft, A G, Christiansen, A A, Munk, H L, Gilbert, L, Jurik, A G, Arnbak, B, Manniche, C, Weber, U, Østergaard, M, Pedersen, S J, Barington, T, Junker, P, Hørslev-Petersen, K, Hendricks, O, Hermansen, L T, Loft, A G, Christiansen, A A, Munk, H L, Gilbert, L, Jurik, A G, Arnbak, B, Manniche, C, Weber, U, Østergaard, M, Pedersen, S J, Barington, T, Junker, P, Hørslev-Petersen, K, and Hendricks, O

Abstract

OBJECTIVES: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP).METHOD: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a positive human leucocyte antigen (HLA)-B27 status plus one clinical SpA feature, characterized as 'non-axSpA'; (c) 82 non-specific LBP patients; (d) 40 healthy blood donors and (e) 43 patients with diagnosed ankylosing spondylitis (AS) served as the negative and positive control groups.RESULTS: There was no difference in IgG and IgA seropositivity against all serotypes between the axSpA, non-axSpA, and LBP groups. No significant correlations were found between anti-Klebsiella antibodies and age, gender, HLA-B27, or high-sensitivity C-reactive protein (hsCRP). IgG seropositivity against K50 was more frequent in AS (25.6%) than in axSpA (13.5%, p < 0.05). axSpA patients with radiographic sacroiliitis and AS controls concordantly had the highest frequency of seropositivity for ≥ 2 serotypes (21%).CONCLUSIONS: The antibody patterns against K. pneumoniae serotypes K2, K26, K36, and K50 did not discriminate between early axSpA and non-specific LBP.

Published
2017

16. Fingerprint biomarkers of type I and III collagen in axial spondyloarthropathy (axspa) and psoriatic arthritis (psa). Association with disease activity and diagnostic capacity

Author

Gudman, N. S., Christensen, A. F., Sorensen, G. L., Jensen, Anne-Christine Bay, Siebuhr, A. S., Karsdal, M. A., Munk, H. L., Ejstrup, L., Loft, A. G., and Junker, P.

Subjects
finger dermatoglyphics *spondyloarthropathy *psoriatic arthritis *disease activity *diagnosis *American *college *rheumatology *health practitioner *human patient turnover time connective tissue spondylarthritis area under the curve enthesitis synovitis smoking receiver operating characteristic metabolism dynamics skeleton rank sum test bone blood level gender ankylosis extracellular matrix Ankylosing Spondylitis Disease Activity Score *biological marker *collagen collagen type 1 marker
Abstract

Background/Purpose: AxSpA and PsA are core members of the spondyloarthritis complex. One cardinal characteristic shared by these two conditions is increased remodeling of bone and soft connective tissue in and around peripheral joints, axial skeleton and entheseal insertions leading to synovitis, enthesitis and ankylosis in advanced disease. Studies using seromarkers which reflect extracellular matrix constituent metabolism may provide insight into the activity and dynamics of connective remodeling and thereby pave the way for improved diagnostics and management. The aims of this investigation were to study C1M and C3M, which reflect the turnover of collagen I and III, in order to assess their utility as diagnostic and disease activity markers. Methods: Ninety-nine patients with PsA, 110 with axSpA and 120 healthy control subjects were included. Demographic and clinical disease measures were recorded.C1M and C3M were quantified using in house competitive ELISAs. Biomarker results are presented as median with 95% CI. Mann Whitney test was applied for inter-group comparisons and correlations were studied using Spearmans test. Receiver operator characteristics (ROC) curve analysis was carried out to evaluate the diagnostic potential of the biomarkers. Results: C1M and C3M were significantly increased in both axSpA and PsA as compared with healthy controls (Figure). Thus, in axSPA C1M and C3M amounted to 77.6 (71.3-84.6)ng/ml and 27.7 (26.2-29.7)ng/ml respectively, in PsA to 85.6 (78.2-96.2)ng/ml and 28.7 (26.7-31.0)ng/ml versus controls 48.3(43.3-53.2) and 20.9 (20.0-21.7) respectively. C1M and C3M levels did not differ significantly between axSpA and PsA. Serum levels of C1M and C3M were not affected by treatment, or smoking status, but SpA HLA-B27+ patients had significantly higher levels of both C1M (p=0.001) and C3M (p=0.006) compared to HLAB-27- SpA patients. C1M was significantly correlated with DAS28 (PsA: r=0.22, p=0.028, SpA: r=0.40, p0.0001 in all groups) but they did not correlate with demographics including age, BMI or gender. Segregation between healthy and diseased based on C1M levels resulted in an AUC of 0.83 for PsA (0.76-0.86) and 0.79 (0.73-0.84) for SpA. C3M could also segregate between healthy and diseased with an AUC of 0.77 (0.71-0.82) for PsA and 0.78 (0.72-0.83) for SpA. Conclusion: These findings indicate that soft connective tissue remodeling is equally increased in axSpA and PsA reflecting disease activity and that collagen type I and III turnover are mediated by closely coupled mechanisms. ROC curve analyses suggest that both C1M and C3M may be useful for diagnostic purposes in axSpA and PsA. (Figure Presented).

Published
2015
Full Text
View/download PDF

18. Heritability assessment of cartilage metabolism. A twin study on circulating procollagen IIA N-terminal propeptide (PIIANP).

Author

Munk, H. L., Svendsen, A. J., Hjelmborg, J. v.B., Sorensen, G. L., Kyvik, K. O., and Junker, P.

Abstract

Objective The aim of this investigation was to estimate the heritability of circulating collagen IIA N-terminal propeptide (PIIANP) by studying mono- and dizygotic healthy twin pairs at different age and both genders. Design 598 monozygotic (MZ) and dizygotic (DZ) twin individuals aged 18-59 years were recruited from the Danish Twin Registry. PIIANP was measured by competitive ELISA. The similarity of circulating PIIANP among MZ and DZ twins was assessed by intraclass correlations according to traits. The heritability was estimated by variance component analysis accounting for additive and dominant genetic factors as well as shared and non-shared environment but ignoring epistasis (genetic inter-locus interaction) and gene-environment interaction. Results The intraclass correlation of PIIANP in MZ and DZ twins was 0.69 (0.60-0.76) and 0.46 (0.34-0.58) respectively indicating a significant genetic impact on PIIANP in serum. Additive genetic effects explained 45% (21-70%), shared environment 24% (7-53%) and non-shared environment 31% (24-39%) of the total variance. The heritability estimate did not differ across ages and between genders. Conclusions The study shows that approximately 45% of the collagen IIA synthesis as assessed by the collagen IIA N-terminal propeptide in serum is attributable to genetic effectors while individual and shared environment account for 24% and 31% respectively. The heritability does not differ between genders or according to age. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

20. No diagnostic utility of antibody patterns against Klebsiella pneumoniae capsular serotypes in patients with axial spondyloarthritis vs. patients with non-specific low back pain: a cross-sectional study.

Author

Hermansen LT, Loft AG, Christiansen AA, Munk HL, Gilbert L, Jurik AG, Arnbak B, Manniche C, Weber U, Østergaard M, Pedersen SJ, Barington T, Junker P, Hørslev-Petersen K, and Hendricks O

Subjects
Adolescent, Adult, Bacterial Capsules immunology, C-Reactive Protein immunology, Case-Control Studies, Denmark, Female, HLA-B27 Antigen genetics, Humans, Immunoglobulin A immunology, Immunoglobulin G immunology, Magnetic Resonance Imaging, Male, Sacroiliitis diagnostic imaging, Sacroiliitis genetics, Serogroup, Spondylarthropathies diagnostic imaging, Spondylarthropathies genetics, Spondylitis, Ankylosing diagnostic imaging, Spondylitis, Ankylosing genetics, Spondylitis, Ankylosing immunology, Young Adult, Antibodies, Bacterial immunology, Klebsiella pneumoniae immunology, Low Back Pain immunology, Sacroiliitis immunology, Spondylarthropathies immunology
Abstract

Objectives: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP)., Method: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a positive human leucocyte antigen (HLA)-B27 status plus one clinical SpA feature, characterized as 'non-axSpA'; (c) 82 non-specific LBP patients; (d) 40 healthy blood donors and (e) 43 patients with diagnosed ankylosing spondylitis (AS) served as the negative and positive control groups., Results: There was no difference in IgG and IgA seropositivity against all serotypes between the axSpA, non-axSpA, and LBP groups. No significant correlations were found between anti-Klebsiella antibodies and age, gender, HLA-B27, or high-sensitivity C-reactive protein (hsCRP). IgG seropositivity against K50 was more frequent in AS (25.6%) than in axSpA (13.5%, p < 0.05). axSpA patients with radiographic sacroiliitis and AS controls concordantly had the highest frequency of seropositivity for ≥ 2 serotypes (21%)., Conclusions: The antibody patterns against K. pneumoniae serotypes K2, K26, K36, and K50 did not discriminate between early axSpA and non-specific LBP.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results